Transcode Therapeutics, Inc. 8-K

What Happened

• TransCode Therapeutics, Inc. announced on June 18, 2026 (via an 8‑K, Item 7.01) that it posted a presentation to its website that the company may use with investors, analysts, collaborators, vendors or other third parties.
• The presentation was furnished (not filed) as Exhibit 99.1 to the Current Report on Form 8‑K.

Key Details

• Filing date: June 18, 2026 (Form 8‑K, Item 7.01, Regulation FD Disclosure).
• Exhibit included: 99.1 — Presentation dated June 18, 2026 (furnished).
• The filing also lists a Cover Page Interactive Data File as an exhibit (Exhibit 104, Inline XBRL reference).
• No financial results, executive changes, mergers, or other material corporate actions were disclosed in this 8‑K.

Why It Matters

• The posting gives investors and analysts access to the company’s current investor presentation materials; such disclosures can include updates on strategy, programs or milestones (review the actual slide deck for specifics).
• Because the presentation was furnished under Regulation FD, TransCode is making the information broadly available but did not file new financial statements or report other material events in this filing. Investors should read Exhibit 99.1 on the company website or in the 8‑K to see any program or pipeline details.